The Immunohistochemical Expression of DNA Topoisomerase II-alpha and E2F-1 in the Breast Carcinoma and Their Relationship with Clinicopathologic Factors.
- Author:
Hang Yun KIM
1
;
Hyun Muck LIM
;
Tae Jin LEE
;
Sung Jun PARK
;
Sung Jae CHA
;
Beom Gyu KIM
Author Information
1. Department of Surgery, College of Medicine, Chung-Ang University, Seoul, Korea. limmhm@kornet.net
- Publication Type:Original Article
- Keywords:
Infiltrating ductal carcinoma;
Breast;
Topoisomerase II-alpha;
E2F-1
- MeSH:
Breast Neoplasms*;
Breast*;
Carcinoma, Ductal;
DNA Topoisomerases, Type I*;
DNA*;
Estrogens;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Transcription Factors
- From:Journal of the Korean Surgical Society
2003;64(2):93-100
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Clinical courses of breast cancer are very different, and concern for finding a predictable marker of breast carcinomas has increased. This study focused on the relationship between the expressions of DNA topoisomerase II-alpha as a proliferative marker, and E2F-1 as a transcription factor, with clinicopathological factors of infiltrating duct carcinomas of the breast. METHODS: We investigated the expressions of E2F-1 and DNA topoisomerase II-alpha in 43 patients with infiltrating ductal carcinomas using immunohistochemical staining, and the results were analyzed with regard to clinicopathological parameters. RESULTS: Among 43 infiltrating ductal carcinomas, 24 (55.8%) were immunohistochemically negative on E2F-1 and 19 (44.2%) were positive. The expression of E2F-1 correlated with increased tumor size, positive axillary lymph node meta stasis and high stage. The topoisomerase II-alpha index correlated with increased tumor size, positive lymph node metastasis, high stage, high histological grade and negative estrogen receptor. The expression of E2F-1 and the topo II-alpha index were significantly correlated. CONCLUSION: These results suggest that the expressions of DNA topoisomerase II-alpha and E2F-1 play some role as prog nostic factors for infiltrating duct carcinomas of the breast, but much more study will be required.
